Carmen Mignogna

Pubblicazioni

Titolo Pubblicato in Anno
Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study DIABETES, OBESITY AND METABOLISM 2024
No differences in kidney function decline between people with type 2 diabetes starting a sodium-glucose cotransporter 2 inhibitor or a glucagon-like peptide-1 receptor agonist: a real-world retrospective comparative observational study CLINICAL THERAPEUTICS 2024
Sex Differences in Cardiovascular Disease and Cardiovascular Risk Estimation in Patients With Type 1 Diabetes THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 2023
Short-term effectiveness of dapagliflozin versus {DPP}-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION 2023
Lack of Association between Serum Chitotriosidase Activity and Arterial Stiffness in Type 2 Diabetes without Cardiovascular Complications INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2023
Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus CARDIOVASCULAR DIABETOLOGY 2023
Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus DIABETES & METABOLISM 2023
MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus DIABETES & METABOLISM 2023
Development of a clinical risk score to predict death in patients with COVID-19 DIABETES/METABOLISM RESEARCH AND REVIEWS 2022
Diastolic Pressure And Acr Are Modifiable Risk Factors Of Arterial Stiffness In T2DM Without Cardiovascular Disease THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 2022
Reduced early response to SARS-CoV2 vaccination in people with type 1 and type 2 diabetes, a six months follow-up study: The CoVaDiab study I DIABETES/METABOLISM RESEARCH AND REVIEWS 2022
Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study DIABETES RESEARCH AND CLINICAL PRACTICE 2021
Effects of the COVID-19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study DIABETES, OBESITY AND METABOLISM 2021
Short-term safety profile of Sars-Cov2 vaccination on glucose control. Continuous glucose monitoring data in people with autoimmune diabetes DIABETES RESEARCH AND CLINICAL PRACTICE 2021
Impact of cardiovascular disease on clinical outcomes in hospitalized patients with Covid-19. a systematic review and meta-analysis INTERNAL AND EMERGENCY MEDICINE 2021
Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes EXPERT OPINION ON INVESTIGATIONAL DRUGS 2021
Adult-onset autoimmune diabetes in 2020: An update MATURITAS 2020
Clinical features of patients with type 2 diabetes with and without Covid-19: a case control study (CoViDiab I) DIABETES RESEARCH AND CLINICAL PRACTICE 2020
Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors. A multicentre retrospective study (CoViDiab II) CARDIOVASCULAR DIABETOLOGY 2020
Chitotriosidase Activity Is Inversely Associated with Diastolic Blood Pressure and HbA1c but Not with Arterial Stiffness in Patients with Type 2 Diabetes without Complications Diabetes 2019

Progetti di Ricerca

Gruppi di ricerca

Intervento farmacologico inibente la differenziazione delle cellule mieloidi verso un fenotipo calcificante
Slowly progressive autoimmune diabetes: a clinical model for novel pathways of ß-cell protection
Synergies anchoring to gravity (SynErg): a novel test to diagnose risk of falls in type 2 diabetes patients

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma